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A new synthetic bone grafting substitute (NanoBone®, ARTOSS GmbH, Germa-
ny) is presented. This is produced by a new technique, the sol-gel-method. This
bone grafting substitute consists of nanocrystalline hydroxyapatite (HA) and
nanostructured silica (SiO2). By achieving a highly porous structure good osteo-
conductivity can be seen. In addition, the material will be completely biodegrad-
ed and new own bone is formed. It has been demonstrated that NanoBone® is
biodegraded by osteoclasts in a manner comparable to the natural bone remo-
delling process.
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INTRODUCTION
The application of bone grafting substitutes is of
increasing interest for dental and craniofacial sur-
gery. The substitutes should promote the formation
of new natural bone, while the external material
should be degraded. To achieve this result the opti-
mal bone grafting substitute must be degraded in
the way natural bone is always degraded — bone
remodelling. Through this natural process a perma-
nent regeneration and optimisation of the skeletal
system in vivo takes place [1].
In the past mostly ceramic materials, especially
those based on hydroxyapatite (HA) and b-tricalcium
phosphate (b-TCP), were used to treat osseous de-
fects. The reason for this is that a large fraction of
human bone consists of hydroxyapatite in its inor-
ganic phase. The conventional bioceramics of animal
or synthetic origin were produced in methods where
sintering on temperatures between 1100°C to 1500°C
occurred. This sintering results in a higher density of
the material and decreasing porosity [2, 3]. In addi-
tion, connectivity between the pores is lost to a con-
siderable degree. The result is decreased osteocon-
ductivity and poor or no degradation of the biomate-
rial, which remains at the site of implantation. Very
often HA particles can be found clinically many years
later. The disadvantage of this behaviour is the nega-
tive impact of mechanical properties and sometimes
the problem of chronic resorptive inflammation.
THE CONCEPT OF NANOBONE®
NanoBone® is produced by the sol-gel-method
[4]. It was approved in Europe (CE-certificate) in Jan-
uary 2005. In the manufacture of NanoBone® the
temperature is always below 700°C, so that no sin-
tering of the nanocrystalline hydroxyapatite takes
place. During the sol-gel-method nanocrystalline hy-
droxyapatite is introduced into the SiO2-sol and ho-
mogeneously distributed. The silica forms a nanop-
orous scaffold during the gel transition and connects
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the loosely packed hydroxyapatite crystallites.
Through the disappearance of the solvent during
the drying process at 200°C a formation of pores in
the micrometre range occurs. Afterwards a highly
porous granulate is produced. Because of the high
porosity and loose packaging of the granulate (in
a “fir-cone shape”) the solid content is approximate-
ly only 20 volume percent. In contact with the pa-
tient’s blood during the operation approximately
80 volume percent is filled with the patient’s own
material. In particular, the patient’s own proteins
can enter the nanopores of the new bone grafting
material.
ANIMAL EXPERIMENTS
Conventional sintered bone grafting substitutes
and the new biomaterial NanoBone® were tested
in clinical trials on mini-pigs from Goettingen.
A perforating critical size defect in the region of
the anterior mandible with a volume greater than
5 cm3 was, therefore, created. There was no con-
tact with the oral cavity or the teeth system. After
8 months the animals were sacrificed. Histological
Figure 1. Sintered hydroxylapatite after 8 months. A degradation
of the biomaterial is observable. An encapsulation of the parti-
cles can be seen.
Figure 2. After 8 months NanoBone® is almost completely
degraded. Compacta and spongious bone have been formed.
cuts were prepared and histomorphometrically
analysed (Fig. 1).
In the defects treated with sintered HA an en-
capsulation of the biomaterial was observed. Defects
treated with NanoBone® were almost completely
healed (Fig. 2). The new bone grafting substitute was
almost completely degraded by osteoclasts. In par-
allel to this new bone tissue in the former defect
region was formed and new compacta and spon-
gious tissue can be seen.
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